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Abstract
Aim Recent studies have reported an association between low vitamin D levels and diabetic peripheral neuropathy.
However, many of these did not differentiate between people with painful diabetic peripheral neuropathy and those with
painless diabetic peripheral neuropathy, or assess major confounding factors including sunlight exposure and daily
activity. Our study addressed these limitations and evaluated vitamin D levels in people with carefully phenotyped
diabetic peripheral neuropathy and controls.
Methods Forty-five white Europeans with Type 2 diabetes and 14 healthy volunteers underwent clinical and
neurophysiological assessments. People with Type 2 diabetes were then divided into three groups (17 with painful
diabetic peripheral neuropathy, 14 with painless diabetic peripheral neuropathy and 14 with no diabetic peripheral
neuropathy). All had seasonal sunlight exposure and daily activity measured, underwent a lower limb skin biopsy and
had 25-hydroxyvitamin D measured during the summer months, July to September.
Results After adjusting for age, BMI, activity score and sunlight exposure, 25-hydroxyvitamin D levels (nmol/l) (SE)
were significantly lower in people with painful diabetic peripheral neuropathy [painful diabetic peripheral neuropathy
34.9 (5.8), healthy volunteers 62.05 (6.7), no diabetic peripheral neuropathy 49.6 (6.1), painless diabetic peripheral
neuropathy 53.1 (6.2); ANCOVA P = 0.03]. Direct logistic regression was used to assess the impact of seven
independent variables on painful diabetic peripheral neuropathy. Vitamin D was the only independent variable to make
a statistically significant contribution to the model with an inverted odds ratio of 1.11. Lower 25-hydroxyvitamin D
levels also correlated with lower cold detection thresholds (r = 0.39, P = 0.02) and subepidermal nerve fibre densities
(r = 0.42, P = 0.01).
Conclusions We have demonstrated a significant difference in 25-hydroxyvitamin D levels in well-characterized people
with painful diabetic peripheral neuropathy, while accounting for the main confounding factors. This suggests a possible
role for vitamin D in the pathogenesis of painful diabetic peripheral neuropathy. Further prospective and intervention
trials are required to prove causality between low vitamin D levels and painful diabetic peripheral neuropathy.
Diabet. Med. 36: 44–51 (2019)
Introduction
Painful diabetic peripheral neuropathy (painful-DPN) affects
up to a quarter of all people with diabetes and can lead to
significant curtailment of quality of life [1]. People with
painful-DPN can present with various degrees of unremitting
burning, aching and ‘electric shock’ pains in their feet and
legs [2]. Night-time exacerbations and contact hypersensi-
tivity to bed clothes result in loss of sleep, and painful-DPN
can be disabling. The pathophysiology of painful-DPN is
poorly understood, and there are no universally accepted
disease modifying treatments for DPN [3]. The mainstay of
treatment is symptom control with pharmacotherapy, which
has limited efficacy and often dose-limiting side-effects [4].
A recent meta-analysis of six observational studies found
an association between serum vitamin D levels and DPN in
people with Type 2 diabetes [5]. A number of clinical and
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animal studies have also examined the role of vitamin D in
the pathogenesis of DPN. Although the findings have been
inconsistent and occasionally contradictory, they have linked
serum vitamin D levels with DPN [6,7]. The mechanisms that
underpin the associations between vitamin D levels and DPN
are not fully understood [6,7]. Pain sensitivity associated
with low vitamin D levels may be directly mediated by its
action on the dorsal root ganglia, specifically small nerve
fibres [8]. Vitamin D deficiency has also been linked to
hypertension [9], dysglycaemia [10] and dyslipidaemia [11]
that have been implicated as independent risk factors for
DPN [12].
Many studies reporting an association between low
vitamin D levels and DPN did not differentiate between
people with painful-DPN and painless-DPN or assess small
fibre function and morphology on skin biopsy. Moreover,
studies did not evaluate major confounding factors including
seasonal sunlight exposure and daily activity. Vitamin D
may have differing aetiological roles in painful- and painless-
DPN subtypes and there is thus a clear rational for
measuring vitamin D levels in carefully phenotyped people
with DPN, while accounting for potential confounding
factors.
Methods
Study design and participants
Fifty-nine white Europeans [without diabetes, n=14; Type
2 diabetes with no neuropathy (no-DPN), n=14; painless-
DPN, n=14; and painful-DPN, n=17] participated in this
study. People with diabetes were recruited from the
Sheffield Teaching Hospitals NHS Foundation Trust
diabetes database and outpatient clinics between August
2013 and September 2014. All had Type 2 diabetes
diagnosed according to World Health Organization
(WHO) criteria. Exclusion criteria included: non-diabetic
neuropathies, history of alcohol consumption of
> 24 units a week, diabetic neuropathies other than
DPN, neurological or other systemic disorders. People
on either maintenance or high-dose vitamin D supple-
mentation were excluded, as were those using sunbeds.
All participants gave written, informed consent before
participation in the study, which had prior Ethics
Approval by the Sheffield Research Ethics Committee
(Study Number STH15701).
Neuropathy assessment
All those taking part in the study underwent: (1) evalu-
ation of the Douleur Neuropathique-4 (DN4) questionnaire
[13], the painful-DPN group only also completed the
Neuropathic Pain Symptom Inventory; (2) Neuropathy
Impairment Score Lower Limb [NIS(LL)] to assess clinical
peripheral neurological status [14]; (3) cardiac autonomic
function tests using the O’Brien protocol [15], which
included a total of five measurements (heart rate variability
during supine rest, standing, deep breathing, Valsalva
manoeuvre and postural drop in blood pressure); (4) nerve
conduction studies of the sural, common peroneal and
tibial nerves at a stable skin temperature of 31 °C and a
room temperature of 24 °C, using a Medelec electrophys-
iological system (Synergy Oxford Instruments, Oxford,
UK); and (5) detailed quantitative sensory testing to assess
large and small fibre function according to the German
Research Network on Neuropathic Pain (DFNS) protocol
[16] utilizing the Medoc TSA 2 Neurosensory analyser
(Medoc Ltd., Ramat Yishai, Israel). The DFNS protocol
includes seven tests measuring 13 parameters. This
extended quantitative sensory testing protocol assesses the
function of various somatosensory modalities correspond-
ing to specific receptors, peripheral nerve fibres and their
central pathways [17].
An overall neuropathy composite score of NIS(LL)+7
was obtained by combining the NIS(LL) plus seven tests
of nerve function [18]. This is a validated, composite
measure of neuropathy severity that has been used in
epidemiological and population-based studies. Based on
these assessments and the DN4 questionnaire score,
people with Type 2 diabetes were divided into three
groups: (1) no-DPN, people with Type 2 diabetes who
were asymptomatic with normal clinical and neurophys-
iological assessments; (2) painless-DPN; comprising peo-
ple with distal symmetrical polyneuropathy who were
pain-free [18]; and (3) painful-DPN, people with painful
What’s new?
• Although there have been consistent associations
between vitamin D levels and diabetic peripheral
neuropathy, many studies did not differentiate between
people with painful and painless diabetic peripheral
neuropathy, assess major confounding factors including
seasonal sunlight exposure and daily activity, and
lacked detailed assessment of peripheral neuropathy
including measurement of skin intra-epidermal nerve
density.
• Our study addressed these limitations and found a
significant reduction in 25-hydroxyvitamin D levels in
well-characterized people with painful diabetic peripheral
neuropathy.
• Further studies including prospective and intervention
trials are required to prove the causality between low
vitamin D levels and painful diabetic peripheral neu-
ropathy. If causality is confirmed, this will have a
significant impact on clinical practice as there would be a
clear rationale for early screening and treatment for low
vitamin D in people with painful diabetic neuropathy.
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neuropathic symptoms involving the feet and or legs in a
distal symmetrical fashion together with evidence of
peripheral neuropathy[18].
Sunlight exposure and activity measurement
All those taking part in the study completed a validated
sunlight exposure and activity questionnaire [19]. This had
been measured for each month over the preceding 12 months
(Appendix S1) [19]. The final sunlight exposure score was
calculated based on: which parts of the body were exposed as
a percentage of total body surface area using the ‘rule of nine’
(face 9%, plus hands 4%, plus arms 18%, plus legs 36%,
plus some or all trunk 36% (Appendix S2); and duration of
outdoor exposure (‘seldom’, 10 min; ‘occasionally’, 20 min;
‘often’, 80 min).
Vitamin D assay
Vitamin D is a fat-soluble steroid precursor that is mainly
produced in skin by direct exposure to sunlight. The two
most important forms of vitamin D are cholecalciferol (D3)
and ergocalciferol (D2). The human body cannot produce D2
but is ingested in fortified foods or supplements. Vitamin D is
not biologically active and undergoes successive hydroxyla-
tion in liver and kidney to form active 1,25-dihydroxyvita-
min D. The major storage form is 25-hydroxyvitamin D [25
(OH)D] with levels ~ 1000-fold greater than the active 1,25
dihydroxyvitamin D. Hence 25(OH)D measurement is con-
sidered to be adequate to calculate overall vitamin D status.
We used an electrochemiluminescence binding assay for
the quantitative determination of total serum 25(OH)D
(Roche Diagnostics, USA). Blood samples were collected
only during the summer months (July, August and Septem-
ber) to avoid seasonal variation in sunlight exposure. This
assay technique has 100% cross reactivity for 25-hydro-
xyvitamin D3 and 92% cross reactivity for 25-hydroxyvita-
min D2. Interassay variability was 7.1% and intra-assay
variability was 5.2% at 50 nmol/l and 3.4% at 120 nmol/l.
Skin biopsy procedure
Skin biopsy specimens were obtained from the distal calf
(10 cm above the lateral malleolus), in accordance with the
guidelines published by the European Federation of Neuro-
logical Societies on the use of skin biopsy in the diagnosis of
peripheral neuropathy [20]. The biopsy was fixed in fresh
periodate–lysine–paraformaldehyde (2%) for 12–24 h. Tis-
sue was then washed in 0.1 M phosphate buffer and stored
for 2–3 days in 15% sucrose in 0.1 M phosphate buffer.
After embedding in OCT (Fisher Scientific UK Ltd), the tissue
was snap-frozen and stored at 80 °C. Section (15 lm)
sections were cut with a freezing microtome for assessment
of intra-epidermal and sub-epidermal nerve fibre density.
Sections were incubated overnight with primary antibodies
to the structural nerve marker PGP9.5 (1 : 40 000; Ultra-
clone, Wellow, UK), detected using avidin–biotin peroxidase
methods (Vector Laboratories, Peterborough, UK) giving
black, positive immunostaining as described previously [21].
Tissue sections were counterstained for nuclei in 0.1% w/v
aqueous neutral red. Omission of primary antibodies and
sequential dilution of antibodies gave appropriate results for
specificity.
Intra-epidermal nerve fibres were counted along the length
of four non-consecutive sections as described and validated
previously [22]. The length of epithelium in each counted
section was measured using computerized microscopy soft-
ware (Olympus ANALYSIS 5.0 Soft, Olympus UK, South-
end, UK) and results expressed as fibres/mm length of
section. Sub-epidermal nerve fibres were measured by image
analysis where digital photomicrographs were captured via
video link to an Olympus BX50 microscope with a depth of
200 lm below the basal epidermis [22]. The grey-shade
detection threshold was set at a constant level to allow
detection of positive immunostaining and the area of
highlighted immunoreactivity was obtained as a percentage
(% area) of the field scanned. Images were captured (940
objective magnification) along the entire length and the mean
values were used for statistical analysis. Quantification was
performed by two independent blinded observers and there
was no significant difference between observers.
Statistical analysis
All analyses were performed using the statistical package
SPSS Version 24.0 (SPSS, IBM Corp, Armonk, NY, USA).
Baseline characteristics were described as mean and standard
deviations (SD) and percentages for categorical variables.
One-way analysis of variance (ANOVA) was used to
compare mean of baseline characteristics and post hoc
analysis to make comparisons between the group means.
Analysis of covariance (ANCOVA) was performed to exam-
ine differences in mean serum vitamin D levels between the
study groups using sunlight exposure score, activity score,
age and BMI as covariates. Direct logistic regression was
performed and odds ratio calculated to assess the impact of
various independent factors on painful-DPN. We also
examined the relationship between serum vitamin D levels
and demographic variables, markers of DPN severity, pain
severity, intra-epidermal nerve fibre density and autonomic
function scores using Pearson’s correlation for parametric
variables, and Spearman’s rank correlation for non-para-
metric variables.
Results
Table 1 summarizes demographic details and study assess-
ments performed for each group. DPN groups had higher
BMI (ANOVA P=0.02) and were older (P=0.009) compared
with healthy volunteers and the no-DPN group. There were
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no significant differences in estimates of sunlight exposure
(P=0.65) or outdoor activity between study groups (P=0.46;
Table 1). The DPN groups had longer duration of diabetes
but there was no significant difference in HbA1c between
them (P=0.63). Table 2 shows clinical, neurophysiological
and skin biopsy data for the different groups. Neuropathy
groups had significantly high NIS(LL)+7 scores and very low
intra-epidermal nerve fibre density (P<0.01) indicating well
established DPN. Quantitative sensory testing parameters
were abnormal in the neuropathy groups; however, the cold
detection threshold was significantly lower in the painful-
DPN compared with the painless-DPN group.
After adjusting for age, BMI, activity score and sunlight
exposure, 25(OH)D levels (nmol/l) (SE) were significantly
lower in painful-DPN [34.9 (5.8), healthy volunteers 62.05
(6.7), no-DPN 49.6 (6.1), painless-DPN 53.1 (6.2);
ANCOVA P=0.03; Fig. 1]. Pairwise comparisons revealed
main group difference between painful-DPN vs. painless-
DPN (P = 0.02) and painful-DPN vs. healthy volunteers
(P = 0.002). Direct logistic regression was performed to
assess the impact of seven independent variables (age, BMI,
sunlight exposure score, activity score, diabetes duration,
mean arterial blood pressure and vitamin D level) on painful-
DPN. The full model containing all predictors was statisti-
cally significant [x2 (7, N = 40) = 17.3, P = 0.01]. As shown
in Table 3, vitamin D was the only independent variable that
made a statistically significant contribution to the model with
an inverted odds ratio of 1.11. This suggests that for each
unit reduction in vitamin D the odds of painful-DPN
increased by a factor of 1.11.
Table 1 Demographic characteristics, sunlight exposure and activity scores
Healthy volunteer No DPN Painless DPN Painful DPN
Post hoc P-value
comparing painful
and painless DPN
n 14 14 14 17
Age (years) 521 (118) 554 (82) 632 (84) 618 (97) 070
BMI (kg/m2) 261 (46) 301 (67) 311 (55) 328 (56) 041
Diabetes duration (years)* – 6.5 (6.0) 145 (70) 150 (22.0) 070
HbA1c (mmol/mol) – 62 (21) 62 (6) 67 (17) 043
HbA1c
(%)
7.9 (1.9) 7.9 (0.6) 8.3 (1.6)
Total cholesterol (mmol/l)* – 41 (1.4) 32 (08) 40 (16) 001
Urine ACR (mg/mmol)* – 06 (09) 41 (7.2) 3.3 (30.1) 014
eGFR (ml/min/1.73m2)* - 82 (17.5) 77.0 (235) 69.5 (225) 038
MAP (mmHg) 911 (128) 10149 (74) 95 (110) 102 (107) 009
Sunlight exposure score 347 (176) 305 (125) 384 (149) 389 (296) 095
Activity score* 11.0 (4.0) 11.0 (3.0) 100 (4.0) 10 (4.0) 031
Scores are given as mean (SD), except *median (i.q.r.).
DPN, diabetic peripheral neuropathy; ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration rate; MAP, mean arterial
pressure
Table 2 Neuropathy parameters
Healthy volunteers No DPN Painless DPN Painful DPN
Post hoc P-value
comparing painful and
painless DPN
NISLL+7 score 09 (13) 15 (11) 19 (186) 255 (130) 003
DN4 score 0 (0) 021 (05) 19 (08) 58 (17) <001
CDT (°C) 283 (17) 257 (28) 206 (113) 112 (103) <001
WDT (°C) 382 (34) 393 (36) 462 (33) 470 (28) 0.50
TSL (°C) 106 (57) 157 (85) 308 (121) 385 (114) 0.03
IENFD (fibres/mm) 57 (1.4) 62 (31) 0.85 (1.6) 077 (1.7) 0.91
SENFD (% area) 11 (05) 19 (10) 043 (06) 016 (02) 0.28
O’Brien autonomic function score 0 (0) 0.15 (0.55) 1.3 (1.3) 1.6 (2.2) 0.50
HRV with deep breath 1.4 (0.09) 1.4 (0.17) 1.19 (0.07) 1.19 (0.09) 0.97
Values are given as mean (SD).
DPN, diabetic peripheral neuropathy; NISLL+7, Neuropathy Impairment Score of the Lower Limb plus 7 tests of nerve function; DN4,
Douleur Neuropathique-4 painful neuropathy score; CDT, cooling detection threshold; WDT, warm detection threshold; TSL, thermal
sensory limen; IENFD, intra-epidermal nerve fibre density; SENFD, sub-epidermal nerve fibre density; HRV, heart rate variability.
*ANOVA P < 0.01; post-hoc analysis revealed no significant differences in mean neurophysiological measures between healthy volunteers
and no-DPN, (P > 0.05), except for SENFD, (P = <0.01). Significant differences in post-hoc analysis were seen between healthy volunteers
and the no-DPN with neuropathy groups (painless- and painful-DPN; P < 0.01).
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There was also a significant negative correlation between
serum 25(OH)D levels and pain scores (DN4; r = 0.30,
P = 0.02; Fig. 2). However, there was no significant corre-
lation between 25(OH)D and nerve conduction studies,
markers of large fibre neuropathy. There were significant
correlations between 25(OH)D and either cold detection
threshold (r = 0.39, P = 0.02) and thermal sensory limen
(r = 0.34, P = 0.04). There was a significant negative
correlation between HbA1c and serum 25(OH)D levels
(r = 0.36, P = 0.01). Autonomic function tests showed
significant reduction in total O’Brien score and heart rate
variability during deep breath in the neuropathy groups but
was reduced equally in both groups (Table 2). Hence
pairwise comparison showed, there was no difference
between painful- and painless-DPN (total O’Brien autonomic
score; post hoc P = 0.5 and heart rate variability; P = 0.97).
There was a positive correlation between heart rate variabil-
ity during deep breath and vitamin D (r = 0.29, P = 0.03)
but this was not prominent with a total O’Brien score that
includes five autonomic measurements (r = 0.26,
P = 0.052).
Both intra- and sub-epidermal nerve fibres were signifi-
cantly lower in the painful- and painless-DPN groups
compared with no-DPN and healthy volunteers (ANCOVA
P < 0.01; Table 2; Fig. 3). Because of the well-established
DPN and hence severely reduced intra-epidermal nerve fibre
counts, we were unable to perform correlation analyses for
intra-epidermal nerve fibres, but correlations with sub-
epidermal nerve fibres showed a significant positive correla-
tion between sub-epidermal nerve fibre density and 25(OH)D
levels (r = 0.42, P = 0.01).
Discussion
A number of recent studies have reported reduced vitamin D
levels in DPN [5] although many of these did not assess major
FIGURE 1 Mean 25(OH)D (nmol/l) levels of groups with 95%
confidence interval, showing significant reduction in 25(OH)D in the
Painful-DPN group. ANOVA, P < 0.01; post-hoc pairwise
comparisons showed group differences between Painful-DPN vs
Painless-DPN (P = 0.02) and Painful-DPN vs HV (P = 0.002).
ANOVA, analysis of variance; DPN, diabetic peripheral neuropathy.
Table 3 Logistic regression predicting likelihood of painful-DPN
B SE Wald P Odds ratio
95% CI for odds ratio
Lower Upper
Age 0.10 0.06 2.8 0.09 1.11 0.98 1.25
BMI 0.02 0.06 0.13 0.70 1.02 0.89 1.17
Sunlight exposure 0.002 0.002 0.66 0.41 1.00 0.99 1.0
Activity score* 0.34 0.20 2.7 0.10 1.40 0.94 2.12
Vitamin D* 0.05 0.02 4.9 0.02 1.11 1.0 1.11
Diabetes duration 0.08 0.05 2.5 0.11 1.08 0.98 1.19
MAP 0.07 0.04 2.9 0.08 1.07 0.98 1.17
Constant 11.18 6.9 2.6 0.10 0.00
MAP, mean arterial blood pressure.
*Inverted odds ratio.
FIGURE 2 Nonparametric correlation between pain score DN4 and
vitamin D [25(OH)D] levels (nmol/l) showing significant negative
correlation. DPN, diabetic peripheral neuropathy.
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confounding factors including seasonal sunlight exposure and
daily activity. In addition, most studies did not differentiate
between painful-DPN and painless-DPN [23]. There is some
evidence, although not consistent, that vitamin D supplemen-
tation improves painful neuropathic symptoms [24], suggest-
ing that vitamin D may have a role in the pathogenesis of
painful-DPN. Our study was designed to address these
limitations by: (1) careful characterization and detailed
phenotyping of DPN, using internationally recognized stan-
dards; (2) restricting the collection of vitaminD blood samples
to during the summer months (July to September); (3)
quantifying sunlight exposure and activity levels, using vali-
dated questionnaires to estimate exposure to UV radiation;
and (4) examining the relationship of vitaminDwithmeasures
of small and large nerve fibre function using quantitative
sensory testing, skin biopsy and nerve conduction studies.
After adjusting for age, BMI, activity score and sunlight
exposure, we demonstrated significantly lower serum 25
(OH)D levels in people with painful-DPN compared with
painless-DPN, no-DPN and healthy volunteers. In our study
cohort with established DPN, a comprehensive cardiac
autonomic function test showed equally reduced scores in
both painful- and Painless-DPN, without any statistically
significant difference between the groups. Although there
was no significant correlation between vitamin D and total
O’Brien autonomic score, there was a trend towards this.
Serum 25(OH)D levels were lowest in people with the
highest reported pain scores. Because pain and thermal
perception are mediated by small sensory fibres, our findings
suggest that vitamin D deficiency may have a role in the
pathogenesis of small-fibre neuropathy particularly affecting
nociceptors, contributing to the development of painful-
DPN. This view is supported by the marked reduction in the
cold detection threshold, considered to be mediated by Ad
fibres, in the painful-DPN group, and the significant corre-
lation between vitamin D levels and cold detection threshold.
Further, there was a significant relationship between sub-
epidermal nerve fibre density and vitamin D levels, but not
nerve conduction studies. The nerve conduction studies
included in the NIS(LL)+7 test are predominantly a measure
of large nerve fibre function, whereas skin biopsy is consid-
ered to be the gold standard for diagnosing and assessing
small fibre neuropathy.
Vitamin D has an important role in promoting nerve
growth factor (NGF) secretion. NGF is a target-derived
protein that regulates the phenotype and sensitivity of
nociceptor fibres, and its deficiency may lead to the
development of clinical diabetic small fibre neuropathy
[25]. A vitamin D3 derivative, induced NGF and pre-
vented neurotrophic deficits in streptozotocin-diabetic rats
FIGURE 3 Skin biopsy showing comparable nerve fibres in healthy volunteer controls (HV, A) and Type 2 diabetes without neuropathy (No-DPN,
D). Painful-DPN (B) and Painless-DPN (C) groups had significant and comparable reduction in intra-epidermal (IENFD) and sub-epidermal nerve
fibre density (SENFD). Box chart E shows mean IENFD and box chart F shows mean SENFD based on immunoreactivity for PGP9·5 antibody, with
95% confidence interval. Figure E (IENFD) showed ANOVA, P < 0.01; but post-hoc pairwise comparisons showed no group differences between
Painful-DPN vs Painless-DPN (P =0·91) but both neuropathy groups (Painful and Painless DPN) had significant reduction in IENFD compared to
HV (P = < 0.001)). Figure F (SENFD) ANOVA, P < 0.01 and post-hoc pairwise comparisons between Painful-DPN vs Painless-DPN (P = 0·28).
DPN, diabetic peripheral neuropathy.
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[26]. A recent study has shown positive correlation
between vitamin D and serum NGF in people with Type
1 diabetes and neuropathy [27]. A study in rodents
reported deactivation of vitamin D by the CYP24A1
enzyme in the presence of glucotoxicity [28]. This may
result in decreased vitamin D-mediated NGF secretion,
which in turn could lead to a predominantly small nerve
fibre neuropathy. We evaluated the relationship between
vitamin D and HbA1c and found a significant negative
correlation, suggesting higher glucose load was associated
with lower vitamin D levels. This suggests a possible
mechanistic link between diabetes, vitamin D and neu-
ropathy. The relationship between degeneration of noci-
ceptor fibres and neuropathic pain is complex and future
studies will need to examine this further; however, the
disproportion between surviving nociceptor fibres and
exposure to ‘relative excess’ of NGF might contribute to
neuropathic pain in DPN [25,29].
Limitations of the study include the relatively small cohort
size and the cross-sectional design. To minimize the impact
of sample size, we carefully characterized and matched
people in the different cohorts. The only statistically signif-
icant difference between subgroups was higher BMI and age
for people in the painful-DPN cohort. This was expected, as
age, duration of diabetes and features of the metabolic
syndrome are risk factors for DPN in Type 2 diabetes [30].
To address this, we included BMI and age as covariates in the
ANCOVA, and still found mean serum 25(OH)D levels were
significantly lower in people with painful-DPN. Another
limitation is that our neuropathy cohort had advanced
neuropathy with high NIS(LL)+7 scores, and a few people
had absent intra- and sub-epidermal nerve fibres on distal leg
skin biopsy; however, they were similar in number in the
painful-DPN and painless-DPN groups.
In conclusion, we have conducted a carefully designed
study which included detailed clinical, neurophysiological
and skin biopsy assessment of all those taking part, in order
to accurately stratify the presence of peripheral neuropathy
and neuropathic pain. We also quantified sunlight exposure
and levels of outdoor physical activity, potentially important
confounding factors that have not been examined in previous
studies. Our study included groups of appropriately matched
disease controls (Type 2 diabetes with no DPN), and healthy
volunteers. The findings suggest a role for vitamin D in
painful-DPN compared with painless-DPN. Further long-
term prospective cohort or interventional studies are required
to examine causality, i.e. if low serum vitamin D levels cause
painful-DPN, or if they are a risk factor/surrogate marker for
the development of painful-DPN.
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